

Special Issue

Immunobiology of *Mycobacterium tuberculosis* and Its Implication in Vaccine Design

Message from the Guest Editors

The aim of this Special Issue is to bring together reviews, commentaries, and research articles in the areas of TB immunity that can help drive better vaccine design and vaccination approaches to control or eradicate Mtb. We invite authors to submit work that they view as relevant to these goals, including, but not limited to, the following topics:

- Intravenous BCG and other nontraditional routes of vaccine administration.
- Newly recognized TB antigens, including subdominant and cryptic antigens or antigenic decoys.
- Adjuvant formulations.
- Eradicating dormant and persistent forms of Mtb.
- Prime-boost vaccination with attenuated Mtb or BCG strains.
- Mycobacterium-specific T and B cell responses.

We look forward to receiving your contributions to inspire the TB research community to help eradicate this deadly disease. Dr. Tony W. Ng

Guest Editors

Dr. Tony W. Ng

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Prof. Dr. Steven A. Porcelli

Department of Microbiology and Immunology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/213527

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).